Tricida, Inc. (TCDA) Probability Sentiment 2
Tricida, Inc. (NASDAQ:TCDA) Probability Sentiment SUMMARY Tricida’s kidney disease drug veverimer tumbled down a few [...]
ContraFect Corporation (CFRX) Probability Sentiment
Contrafect Corporation (NASDAQ:CFRX) Probability Sentiment SUMMARY Researchers have struggled with the problem of antibiotic resistance [...]
Codiak (CDAK) to report early exoSTING data; SanaCurrents closing coverage
When SanaCurrents issued a March 19 report forecasting a positive outcome for Codiak Biosciences’ (NASDAQ:CDAK) phase I/II exoSTING trial, the favorable outlook was based [...]
BioXcel Therapeutics, Inc. (BTAI) Probability Sentiment 3
Bioxcel Therapeutics, Inc. (NASDAQ:BTAI) Probability Sentiment SUMMARY After the success of two, phase III confirmatory [...]
FDA to decide on Eton’s (ETON) anti-seizure drug by November 6
In August, the FDA extended the PDUFA date for Eton Pharmaceuticals’ (NASDAQ:ETON) anti-seizure drug ET-101 by three months to November [...]
Clene’s (CLNN) lead drug shows promise in ALS but falls short on key endpoints; SanaCurrents closing coverage
On November 2, Clene, Inc. (NASDAQ:CLNN) reported its RESCUE-ALS phase II trial, testing the drug CNM-Au8, did not meet the [...]
Radius Health, Inc. (RDUS) Probability Sentiment
Radius Health, Inc. (NASDAQ:RDUS) Probability Sentiment SUMMARY Drug developers now target new breast cancer treatments [...]
Spero Therapeutics (SPRO) files NDA; SanaCurrents closing out coverage
After Spero Therapeutics (NASDAQ:SPRO) disclosed early on October 28 it had filed a new drug application (NDA) for its oral [...]